A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

May 31, 2029

Conditions
Solid TumorAdvanced Solid TumorSolid Tumor, AdultMetastatic TumorOvarian CancerOvarian NeoplasmsOvarian CarcinomaMetastatic Ovarian CarcinomaEndometrial NeoplasmsEndometrial DiseasesMetastatic Endometrial CancerTriple Negative Breast CancerMetastatic Endometrial CarcinomaAdvanced Endometrial CarcinomaAdvanced Ovarian CarcinomaGastric CancerAdvanced Gastric CarcinomaMetastatic Gastric CancerMetastatic Gastric CarcinomaSmall Cell Lung CancerSmall Cell Lung CarcinomaTriple Negative Breast NeoplasmsPlatinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaCCNE1 AmplificationHormone Receptor Negative Breast CarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastProgesterone-receptor-positive Breast Cancer
Interventions
DRUG

NKT3964

Oral CDK2 Degrader

Trial Locations (14)

19107

RECRUITING

Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia

22031

RECRUITING

NEXT Virginia, Fairfax

22903

NOT_YET_RECRUITING

University of Virginia, Charlottesville

30322

NOT_YET_RECRUITING

Emory Winship Cancer Institute, Atlanta

32746

RECRUITING

Florida Cancer Specialists & Research Institute, Lake Mary

32804

NOT_YET_RECRUITING

AdventHealth Cancer Institute, Orlando

37203

RECRUITING

Sarah Cannon Research Institute (SCRI), Nashville

72205

RECRUITING

University of Arkansas Medical School, Little Rock

78758

RECRUITING

NEXT Oncology, Austin

80218

RECRUITING

SCRI at HealthOne, Denver

84145

RECRUITING

Intermountain Health, Salt Lake City

94158

NOT_YET_RECRUITING

UCSF, San Francisco

02215

RECRUITING

Dana Farber Cancer Institute, Boston

07601

RECRUITING

John Theurer Cancer Center at Hackensack UMC, Hackensack

Sponsors
All Listed Sponsors
lead

NiKang Therapeutics, Inc.

INDUSTRY

NCT06586957 - A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter